Original Article
Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer

Da Li¹, Qi-Jun Wu², Fang-Fang Bi¹, Si-Lei Chen¹, Yi-Ming Zhou³, Yue Zhao⁴, Qing Yang¹

Departments of ¹Obstetrics and Gynecology, ²Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang 110004, China; ³Department of Medicine, Brigham and Women’s Hospital, Harvard Institutes of Medicine, Harvard Medical School, Boston, MA 02115, USA; ⁴Department of Cell Biology, Key Laboratory of Cell Biology, Ministry of Public Health, and Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang 110001, China

Received January 14, 2016; Accepted February 29, 2016; Epub March 15, 2016; Published March 30, 2016

Abstract: There is accumulating evidence that breast cancer 1 (BRCA1), sirtuin 1 (SIRT1), and epidermal growth factor receptor (EGFR) help to modulate cisplatin cytotoxicity. The role of dynamic crosstalk among BRCA1, SIRT1, and EGFR in cisplatin sensitivity remains largely unknown. We found that BRCA1, SIRT1, and EGFR levels were increased in cisplatin-resistant ovarian cancers compared with those in cisplatin-sensitive ovarian cancers. Hypomethylation in the BRCA1 promoter was associated with BRCA1 activation, significantly elevated SIRT1 levels, decreased nicotinamide adenine dinucleotide (NAD)-mediated SIRT1 activity, and decreased EGFR levels. Treatment with 5 and 10 μg/ml cisplatin induced a gradual increase in BRCA1 and SIRT1 levels and a gradual decrease in NAD levels and NAD-mediated SIRT1 activity, whereas EGFR levels were increased or decreased by treatment with 5 or 10 μg/ml cisplatin, respectively. The overexpression of SIRT1 or the enhancement of SIRT1 activity synergistically enhanced the BRCA1-mediated effects on EGFR transcription. In contrast, the knockdown of SIRT1 or the inhibition of SIRT1 activity inhibited the BRCA1-mediated effects on EGFR transcription. BRCA1 regulates EGFR through a BRCA1-mediated balance between SIRT1 expression and activity. Those results improve our understanding of the basic molecular mechanism underlying BRCA1-related cisplatin resistance in ovarian cancer.

Keywords: BRCA1, SIRT1, EGFR, cisplatin, ovarian cancer

Introduction

Ovarian cancer is the most common gynecological malignancy and is a leading cause of mortality among women worldwide [1]. Although the primary cause of ovarian cancer remains elusive, breast cancer 1 (BRCA1) mutations are major hereditary risk factors [2]. Accumulating evidence demonstrates that BRCA1 and BRCA1-IRIS, the protein product of the BRCA1 locus, play a critical role in determining cisplatin sensitivity [3, 4], presumably through effects on homologous recombination-dependent DNA repair [5]. Little is known, however, about the other mechanisms of involving BRCA1-related cisplatin resistance.

BRCA1 is a tumor-suppressor gene and is widely involved in transcriptional regulation [6, 7], epigenetic modification [8], and cellular metabolism [9]. Previously, we demonstrated a novel interaction between BRCA1 and sirtuin 1 (SIRT1), which might be beneficial for the dynamic balance between BRCA1-related biological processes and SIRT1-related energy metabolism and stress response [10]; and BRCA1 has been implicated as a key transcriptional regulator of epidermal growth factor receptor (EGFR) in ovarian cancer progression [11, 12]. Furthermore, a growing body of evidence suggests that BRCA1, SIRT1, and EGFR play direct or indirect roles in the modulation of cisplatin cytotoxicity [3, 4, 13, 14]. Therefore, we investigated the potential crosstalk among BRCA1, SIRT1, and EGFR in cisplatin-sensitive and cisplatin-resistant ovarian cancer. Our results provide novel insight into the mechanisms involved in BRCA1-related cisplatin resistance.
Materials and methods

Ethical statements

This investigation was conducted in accordance with ethical standards of the Helsinki Declaration of 1975.

Patients and tissue collection

This study was approved by the Institutional Review Board at China Medical University. Patients with serous ovarian cancer (15 chemosensitive and 12 chemoresistant) were enrolled between 2011 and 2014. All enrolled patients gave informed consent. Fresh tumor samples were obtained at the time of primary surgery before any chemotherapy or radiotherapy. Three staff pathologists performed hematoxylin and eosin staining of the samples for histopathological diagnosis and grading using the World Health Organization criteria.

Cell culture, cisplatin treatment, shRNAs, and cell proliferation assay

The human ovarian cancer cell-line A2780 was maintained in RPMI 1640 with 2 mM glutamine and 10% fetal bovine serum (Invitrogen, CA, USA). Cis-Diamineplatinum (II) dichloride was purchased from Sigma (St. Louis, MO, USA). SRT1720 and EX 527 were purchased from Selleck Chemicals (Houston, TX, USA). Lentiviral vectors (Table 1) expressing short hairpin RNAs (shRNAs) against BRCA1 (NM_007299) were obtained from GeneChem Co., Ltd (Shanghai, China). A non-silencing shRNA sequence was used as a negative control. Lentiviral vectors expressing shRNAs for SIRT1 (sc-40986-V) were purchased from Santa Cruz Biotechnology (CA, USA). For the overexpression of SIRT1, the open reading frames of SIRT1 (NM_012238) were cloned into the lentiviral vector GV287 (Ubi-MCS-3FLAG-SV40-EGFP; GeneChem Co., Ltd). Transfections were performed using polybrene and enhanced infection solution (GeneChem Co., Ltd) according to the manufacturer's protocol. The efficiency of BRCA1 and SIRT1 transfection was as previously reported [10, 15]. A2780 cells were treated with 5 or 10 μg/ml cisplatin for 48 h. After 48 h cisplatin treatment, cell proliferation was determined using the Cell-Light™ EdU Apollo® 643 In Vitro Imaging Kit (Ribobio, Guangzhou, China) following the manufacturer's instructions.

DNA methylation analysis by pyrosequencing

Genomic DNA was bisulfite modified using the EpiTect Plus DNA Bisulfite Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. The bisulfite-modified DNA was amplified using the EPIK™ Amplification Kit (Bioline) according to the manufacturer's protocol. The specific primer sequences are listed in Table 1.

### Table 1. Primers used in this study

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primers</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRCA1-SH-F</td>
<td>5'-CGGGAACCTGTTCCTCACAAAGTGTGCTGAGCGCACCTTTGTGGAGACAGTTTTTTTG</td>
<td>Lentiviral packaging sequences for BRCA1 knockdown</td>
</tr>
<tr>
<td>BRCA1-SH-R</td>
<td>5'-AATTCAAAAAAACCTGTTCCTCACAAAGTGTGCTGAGCGCACCTTTGTGGAGACAGTTTTTTTG</td>
<td>Lentiviral packaging sequences for negative control</td>
</tr>
<tr>
<td>BRCA1-CON-F</td>
<td>5'-cgggttccgagaGCTGAGCTGACTctcggagACGTGACACGCTTCGGAGACAAACCT</td>
<td>Real-time PCR for BRCA1</td>
</tr>
<tr>
<td>BRCA1-CON-R</td>
<td>5'-aatctaaaaATTCGGAACCTGTTCCTCACAAAGTGTGCTGAGCGCACCTTTGTGGAGACAGTTTTTTTG</td>
<td>Real-time PCR for SIRT1</td>
</tr>
<tr>
<td>SIRT1-RTP-F</td>
<td>5'-CGGATGATGATGATGAGAGGAGACAAACCT</td>
<td>Real-time PCR for EGFR</td>
</tr>
<tr>
<td>SIRT1-RTP-R</td>
<td>5'-GGGTTGGAGGAGGAGACAAACCT</td>
<td>Methylation analysis for BRCA1</td>
</tr>
<tr>
<td>EGFR-RTP-F</td>
<td>5'-GCGAAATTCCTTTTGGAAAACC</td>
<td>Real-time PCR for GAPDH</td>
</tr>
<tr>
<td>EGFR-RTP-R</td>
<td>5'-AAGGACATGAGGTATTTTCGAGATACA</td>
<td>Real-time PCR for GAPDH</td>
</tr>
<tr>
<td>GAPDH-RTP-F</td>
<td>5'-AGGTTAGGAGGAGGAGACAAACCT</td>
<td>Real-time PCR for GAPDH</td>
</tr>
<tr>
<td>GAPDH-RTP-R</td>
<td>5'-GGTCTATGAGGTGACAAACCT</td>
<td>Real-time PCR for GAPDH</td>
</tr>
</tbody>
</table>

Abbreviations: CON, control; SH, shRNAs; RTP, real-time PCR; F, forward primer; R, reverse primer.
BRCA1 and cisplatin resistance

PyroMark™ Gold Q96 reagents (Qiagen) with subsequent quantification of methylation levels using the PyroMark Q24 1.010 software. The relative differences among peak heights were used to calculate the percentage of methylated cytosines.

Real-time quantitative PCR

Total RNA was extracted using Trizol reagent (Invitrogen) according to the manufacturer’s protocol. DNA contamination was removed by adding DNase I (Invitrogen) according to the manufacturer’s protocol. Total RNA was then reverse-transcribed from 2 μg RNA using the PrimeScript RT Master Mix kit (TaKaRa, Dalian, China) and amplified using SYBR Premix Ex Taq™ II (TaKaRa) in a Roche LightCycler 2.0 (Roche Diagnostics, Mannheim, Germany). The specific primer sequences are listed in Table 1. GAPDH mRNA was amplified as an internal control for the normalization of each sample. All samples were analyzed using the 2^−ΔΔCT method.

Assays of nicotinamide adenine dinucleotide (NAD) levels and SIRT1 activity

For the NAD assay, 20 mg frozen ovarian tissue or 20 μl packed, cultured cells was homogenized in 400 μl BioVision NAD/NADH Extraction Buffer (BioVision, CA, USA). The homogenate was ultrafiltered using BioVision 10-kD cut-off filters (14000 g, 30 min, 4°C). Assays were performed using NAD/NADH Quantification Kits according to the manufacturer’s instructions (BioVision). SIRT1 deacetylase activity was evaluated using a commercially available CycLex SIRT1/Sir2 Deacetylase Fluorometric Assay Kit (Cycllex Co., Ltd., Nagano, Japan) according to the manufacturer’s protocols [10].

Statistical analysis

The data are presented as mean ± standard deviation (SD) or standard error (SE). Statistical differences in the data were evaluated by Student’s t test or one-way analysis of variance (ANOVA) as appropriate, and were considered significant at when \( P < 0.05 \).

Results

BRCA1, SIRT1, and EGFR levels were elevated in cisplatin-resistant cancers

BRCA1 is a potential trigger in the transcriptional regulation of SIRT1 and EGFR in ovarian cancer [10, 12]. The intracellular BRCA1, EGFR, and SIRT1 levels and SIRT1 activity were measured in cisplatin-sensitive and cisplatin-resistant ovarian cancer tissues, respectively. The BRCA1, SIRT1, and EGFR levels were elevated in the cisplatin-resistant cancers compared with those in cisplatin-sensitive cancers (Figure 1A, 1B and 1E). There was no significant difference between the cisplatin-sensitive and cisplatin-resistant cancers, however, in the NAD level or the SIRT1 activity (Figure 1C and 1D).

Cisplatin treatment induced differential BRCA1, SIRT1, EGFR levels and NAD-dependent SIRT1 activity

The effects of cisplatin on the regulation of BRCA1, EGFR, and SIRT1 expression and SIRT1 activity were evaluated in the ovarian cancer-
BRCA1 and cisplatin resistance

cell line A2780. The proliferation of the A2780 cells was gradually inhibited as the concentration of cisplatin in the growth medium was increased from 5 to 10 μg/ml (Figure 2A and 2B). Furthermore, 5 and 10 μg/ml cisplatin induced a gradual increase in BRCA1 and SIRT1 levels (Figure 2C and 2D) and a gradual decrease in NAD levels and NAD-dependent SIRT1 activity (Figure 2E and 2F). EGFR levels were increased by 5 μg/ml cisplatin and decreased by 10 μg/ml cisplatin (Figure 2G). Those results indicate that cisplatin could be responsible for the regulation of BRCA1, EGFR, and SIRT1 expression and NAD-dependent SIRT1 activity.

BRCA1 regulates EGFR expression via SIRT1 in ovarian cancer cells

To further clarify the role of SIRT1 in the regulation of BRCA1-mediated EGFR expression, the effects of BRCA1 knockdown, combined with SIRT1 overexpression or knockdown, and the enhancement or inhibition of SIRT1 activity were evaluated. BRCA1 knockdown effectively increased EGFR levels in the ovarian cancer cells. SIRT1 overexpression or the enhancement of SIRT1 activity synergistically enhanced the BRCA1-mediated effects on EGFR transcription. In contrast, SIRT1 knockdown or the inhibition of SIRT1 activity effectively abolished the BRCA1-mediated effects on EGFR transcription. Those results indicate that SIRT1 might be a key factor in the BRCA1-mediated regulation of EGFR expression (Figure 3).

High BRCA1 levels mediated by promoter hypomethylation are accompanied by increased SIRT1 levels, and decreased of NAD-dependent SIRT1 activity and EGFR expression

In mammals, promoter methylation is an epigenetic modification involved in regulating gene expression [7, 8]. Our previous study suggests that the methylation levels of sites 1-3 accurately represent the methylation levels of the
BRCA1 core promoter [10]. Ovarian cancer tissues with a hypomethylated sites 1-3 (Figure 4A-C) displayed increased levels of BRCA1 compared with ovarian cancer tissues with a hypermethylated BRCA1 promoter (Figure 4D). Therefore, the differential levels of BRCA1 mediated by promoter methylation were an appropriate model for investigating the physiological relationships among BRCA1, SIRT1, and EGFR. The high BRCA1 levels mediated by hypomethylation of the BRCA1 promoter were accompanied by a marked increase in SIRT1 levels (Figure 4E) and a significant decrease in NAD-dependent SIRT1 activity (Figure 4F and 4G) and EGFR expression (Figure 4H).

Discussion

The results demonstrate a novel mechanism of BRCA1-mediated, SIRT1-related transcriptional regulation of EGFR, which could play a significant role in cisplatin cytotoxicity. There is mounting evidence suggesting that BRCA1 plays a role in cisplatin resistance. POU class 1 homeobox 1 (Pit-1) can specifically inhibit BRCA1 expression, sensitizing breast cancer cells to cisplatin therapy [16]. Altered BRCA1 expression can modulate cisplatin sensitivity through the mitochondrial fission program [3]. Some microRNAs, miR-9 [17] and miR-638 [18], affect DNA repair and cisplatin sensitivity via BRCA1 deregulation. BRCA1-IRIS inactivation sensitizes ovarian cancer cells to cisplatin [4]. CDK12 inactivation reduces BRCA1 levels, disrupts homologous recombination-dependent DNA repair, and sensitizes ovarian cancer cells to cisplatin [19].

The results of a number of recent studies collectively drew attention to the possibility that cisplatin sensitivity is influenced by a functional link between BRCA1-mediated SIRT1 transcription and SIRT1-related EGFR expression. SIRT1 can provoke renal fibrogenesis through the activation of EGFR signaling [20, 21]. BRCA1-associated breast cancers are triple-negative, basal-like, high-grade, ductal carcinomas that frequently overexpress EGFR [11]. BRCA1 can regulate EGFR expression in ovarian cancer cells [12] and breast cancer cells [11]. High levels of SIRT1 significantly enhanced cisplatin resistance in HHUA endometrial carcinoma cell lines [22]. SIRT1 silencing can dramatically enhance cisplatin-mediated growth inhibition, G2/M phase arrest, and apoptosis [23]. EGFR overexpression is involved in resistance to cisplatin-based neoadjuvant chemotherapy [14]. Cisplatin can activate EGFR signaling, which in turn might provide a survival advantage for cancer cells [24]. Our current results provide compelling evidence that the balance between SIRT1 expression and activity is a key factor in the BRCA1-mediated regulation of EGFR expression, playing an essential role in the context of cisplatin treatment.

There is a special compensatory mechanism for SIRT1 function. For instance, BRCA1 inactivation inhibits SIRT1 expression, but it also induces a substantial increase in NAD levels and consequently enhances SIRT1 activity [10]. Consistent with those properties, cisplatin-resistant ovarian cancer tissues overexpressed BRCA1 and displayed enhanced SIRT1 function (high levels of SIRT1 with normal SIRT1 activity) and EGFR expression. In addition, 5 and 10 μg/
BRCA1 and cisplatin resistance

A. Primers and Genes

B. BRCA1 hypermethylation (B-hyper) and hypomethylation (B-hypo)

C. Percent methylation (%)

D. Relative BRCA1 levels

E. Relative SIRT1 levels

F. NAD (pmol/mg protein)

G. Relative SIRT1 activity (%)

H. Relative EGFR levels

BRCA1 and cisplatin resistance

Figure 4. Intracellular BRCA1, SIRT1, and EGFR levels and NAD-dependent SIRT1 activity in ovarian cancer with hypomethylated promoter-mediated BRCA1 activation. (A) The location of CpG sites in the core promoter region of BRCA1. Genomic coordinates are shown, along with the primer-amplified fragments, GC percentage, location of individual CpG dinucleotides (dashes), and BRCA1 RefSeq gene (exon 1 is shown as a blue box, and the intron is shown as an arrowed line). The arrow indicates the direction of transcription. (B) Comparative analysis of methylation patterns at sites 1-3 of the BRCA1 core promoter in ovarian cancer tissues. The yellow regions indicate control regions for the automatic assessment of bisulfide conversion (unmethylated C should be fully converted to T), and the blue regions indicate the percentage of CpG methylation. (C) Summary of the methylation levels of the BRCA1 gene from the measurements shown in (B). (D-H) BRCA1 levels, SIRT1 levels, NAD levels, SIRT1 activity, and EGFR levels were measured in ovarian cancer tissues with an identified hypermethylated BRCA1 promoter and compared with those in ovarian cancer tissues with a hypomethylated BRCA1 promoter. Bar graphs show mean ± SE (n = 8 for the hypermethylated group, n = 19 for the hypomethylated group).

ml cisplatin effectively induced a gradual increase in SIRT1 levels and a gradual decrease in SIRT1 activity, respectively. In that regard, EGFR levels were increased or decreased by 5 or 10 μg/ml cisplatin, respectively. Those results suggest that different doses of cisplatin might be responsible for the regulation of EGFR expression through the balance between SIRT1 expression and activity.

Our results support the hypothesis that the BRCA1-SIRT1-EGFR axis is broadly involved in the regulation of cisplatin sensitivity and emphasize the convergence of the BRCA1-mediated antitumor mechanism, the SIRT1-related energy metabolism and stress responses, and the EGFR-mediated cell proliferation pathway. Taken together, those results improve our understanding of the basic molecular mechanism underlying BRCA1-related cisplatin resistance in ovarian cancer.

Acknowledgements

This work was supported by the Clinical Capability Construction Project for Liaoning Provincial Hospitals (LNCCC-A01-2015), Fok Ying Tung Education Foundation (No. 151039), Natural Science Foundation of China (No. 81402130, 31271364), and the Doctoral Start-up Foundation of Liaoning Province (No. 20141045, 201501007).

Disclosure of conflict of interest

None.

Address correspondence to: Qing Yang, Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, Shenyang 110004, China. Tel: 86-024-96615-42111; Fax: 86-024-23892617; E-mail: yangq_cmu@163.com

References

[9] Li D, Chen NN, Cao JM, Sun WP, Zhou YM, Li CY and Wang XX. BRCA1 as a nicotinamide ade-


